Skip to main content

Advertisement

Table 1 Overview of clinical and parasitological parameters assessed for volunteer 1

From: Two cases of long-lasting, sub-microscopic Plasmodium malariae infections in adults from coastal Tanzania

  Study enrolment Routine visit 1 Routine visit 2 qPCR results reported Post-treatment visit 1 Post-treatment visit 2
Timeline
 Date 22/12/2015 13/02/2016 13/04/2016 28/04/2016 06/05/2016 01/07/2016
 Days respective to enrolment into clinical trial 0 53 113 128 136 192
Clinical evaluation
 Body temperature 36.6 °C 36.2 °C 36.8 °C 36.6 °C 37.2 °C
 Vital signs including pulse, blood pressure and respiration rate NAD NAD NAD NAD NAD
Laboratory evaluation
 Biochemistry including ALT, AST NAD, also included BIL and CRE at enrolment NAD NAD NAD NAD
 Complete blood count includes RBC, HGB, HCT, MCV, MCH, MCHC, PLT, WBC with differential NAD NEUT ↑ (3.57 × 103/µL, 72.2%) LYMP ↓ (0.70 × 103/µL, 14.1%) MCHC ↓ (29.7 g/dL) NAD NAD
 Urine analysis using dipstick that includes bilirubin, ketone, creatinine, hematuria, proteinuria, albumin, nitrite, leucocytes, glucose, specific gravity, pH, vitamin C NAD NAD Proteinuria (1+) NAD NAD
 Serology (HIV, HBV, HCV) Negative
 Screening for intestinal helminths and schistosomiasis Negative
Malaria diagnostics
 Thick blood smear microscopy Negative Negative Negative Negative Negative Negative
 Screening and species identification qPCR assays Screening qPCR: Cq of 36.03 ID-qPCR: P. malariae Screening qPCR: Cq of 35.72 ID-qPCR: P. malariae Screening qPCR: Cq of 37.69 ID-qPCR: nega Screening qPCR: Cq of 34.47 ID-qPCR: P. malariae Screening qPCR: neg Screening qPCR: neg
Drug treatment
 Prescription of drugs throughout the clinical trial Start of artesunate-amodiaquine based treatment on 02/05/2016
  1. NAD no abnormalities detected
  2. aPlasmodium species identification qPCR assay was negative due to drop of P. malariae parasitemia (Cq value for 18S Plasmodium spp. screening assay was 37.69)